Fungal infections of the skin (groin and other surfaces of the body, feet, scalp) caused by dermatophytes of the genusTrichophyton andMicrosporum canis andEpidermophyton floccosumwhen the treatment is justified due to the location and extent of the infection. Nail fungus, caused by dermatophytes. Terbinafine used orally is not effective in the treatment of Miscanthus dandruff.
Composition:
1 tabl contains 250 mg of terbinafine hydrochloride.
Action:
The antifungal medicine from the allylamine group inhibits ergosterol biosynthesis in fungal cells. It works on dermatophytes (Trichophyton rubrum, T. mentagrophytes, T. verrucosum, T. tonsurans, T. violaceum, Microsporum canis, Epidermophyton floccosum), molds and some dimorphic fungi, as well as most yeastsCandida spp. It is well absorbed from the digestive tract. It quickly penetrates the stratum corneum, dermis and tissues and deposits in the nail plate. Plasma proteins are 99% bound. Terbinafine is rapidly and extensively metabolised in the liver; its inactive metabolites are mainly excreted in the urine. T0,5 in the elimination phase is 17 hours.
Contraindications:
Hypersensitivity to terbinafine or any of the excipients.
Precautions:
Use in children and patients with liver disease is not recommended. Carefully used in patients with psoriasis (risk of exacerbation of the disease) and in patients with renal insufficiency. If symptoms of liver dysfunction occur, liver enzymes should be checked and terbinafine should be discontinued.
Pregnancy and lactation:
It should not be used during pregnancy unless the potential benefit outweighs the risk. Terbinafine is excreted in breast milk - it should not be used during breastfeeding.
Side effects:
Common: headache, fullness, lack of appetite, indigestion, nausea, mild abdominal pain, diarrhea, rash, urticaria. Uncommon: transient disturbances of taste, including loss. Rare: severe skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, hypersensitivity to light, angioneurotic edema), paresthesia, weakness, dizziness, malaise, fatigue, jaundice, cholestasis, hepatitis, muscle pain and joints. Very rare: exacerbation of psoriasis, neutropenia, agranulocytosis, thrombocytopenia, anaphylactic reactions, onset or exacerbation of dermatological or systemic lupus erythematosus, depression, anxiety. In individual cases: persistent taste disturbances leading to reduced appetite and significant weight loss.
Dosage:
Orally. Adults: 250 mg once a day. Patients with renal insufficiency (creatinine clearance <50 ml / min) are given half the dose. The duration of treatment is usually: in athlete's torso and groins - 2-4 weeks; in the interdigital and plantar-moccasin mycosis - 2-6 weeks; in tineaatosis of the scalp - 4 weeks; in fungal nail infections - 6-12 weeks, in foot mycosis it may be necessary to have 6-month or longer treatment.
(C)
